Search

Displaying results 3111 - 3120 of 10000 in total
  1. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … The most common subtype of MoCD, type A, involves mutations in _MOCS1_ wherein the first step of molybdenum cofactor synthesis - the conversion of guanosine triphosphate into cyclic pyranopterin monophosphate

  2. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis. … Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].

  3. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. … In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

  4. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    [L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production

  5. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. … The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory

    Synonyms: under control of a human cytomegalovirus (CMV) promoter and terminated with a 3' untranslated region and a simian virus 40 (SV40) polyadenylation signal, Replication-deficient gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteins
  7. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    [A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    Molsidomine

    go.drugbank.com/drugs/DB09282
    ApprovedWithdrawn

    Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones. … Interestingly, it is being studied as being a preventive measure in cerebral infarction [A31932].

  9. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology … of various skin inflammatory disorders.

    Synonyms: Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimer
  10. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor.